Navigation Links
Selexis Announces Expansion of R&D License Agreement with Amgen
Date:2/20/2013

GENEVA, Feb. 20, 2013 /PRNewswire/ -- Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that Amgen has expanded their R&D License Agreement with Selexis to include an evaluation of the proprietary Selexis SURE CHO-M Cell Line™ for research and development.  Under the agreement, Amgen will be able to evaluate the SURE CHO-M Cell Line™ in conjunction with the Selexis SUREtech Vectors™ for improved R&D. 

(Logo: http://photos.prnewswire.com/prnh/20120627/LA31604LOGO)

"Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding and stable," said Igor Fisch , Ph.D., President and CEO of Selexis. "Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently.  This current agreement is built on the long-standing relationship between our two companies since 2004." 

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information, visit http://www.selexis.com

Media Inquires
Robert Meister
Selexis SA
Tel: +1 (602) 953-1716
Email: robert.meister@selexis.com

 


'/>"/>
SOURCE Selexis SA
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
2. Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call
3. Incisive Surgical Announces Sale Of One-Millionth INSORB Stapler
4. BioMed Realty Trust Announces Exercise Of Option To Purchase Additional Shares Of Common Stock
5. UBM Canon, the Global Authority on the MedTech Industry, Announces Senior Editor for MD+DI (Medical Device & Diagnostic Industry)
6. Silver Lining Textiles, Manufacturers of Anti-microbial Under Scrub Garments for the Healthcare Industry, Announces Their Availability Through Amazon.com
7. NxStage Announces CE Mark Approval for Nocturnal Home Hemodialysis
8. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
9. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
10. Vomaris Announces initiation of study with Walter Reed National Military Medical Centers Combat Wound Initiative
11. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2019)... ... December 06, 2019 , ... Plant Life Company announced ... LLC (a division of Horticultural Holdings LLC) to recommend Plant Life Company’s line ... FFGS is a team of disciplined and energetic plant lovers formally educated in ...
(Date:12/5/2019)... ... December 05, 2019 , ... Intelligent.com, ... the Top 27 Respiratory Therapy Degree Programs for 2020. The comprehensive research guide ... nation. Each program is evaluated based on curriculum quality, graduation rate, reputation, and ...
(Date:12/5/2019)... ... , ... nView, a leading behavioral health solutions company, is ... Product Officer. As the company expands its portfolio of software solutions, Rosenbaum will ... into nView’s product and company growth strategy. Rosenbaum will report directly to nView ...
Breaking Medicine Technology:
(Date:12/8/2019)... ... , ... More than 85 million people across the United States currently suffer ... Dermatology, indicating this problem is more common than previously believed. Studies show the numbers ... dermatological conditions vary in type and severity and span all age groups. In response ...
(Date:12/6/2019)... SAN JOSE, Calif. (PRWEB) , ... December 06, ... ... entering into the era of assembling and manufacturing implantable medical devices, which is ... , As the name suggests, implantable medical devices are surgically inserted into ...
(Date:12/6/2019)... HUNTINGTON, N.Y. (PRWEB) , ... December 06, ... ... they are now the preferred HIPAA compliance solution for the Wyoming Medical Society. ... HIPAA compliance. , Healthcare entities have an obligation to adhere to the ...
(Date:12/5/2019)... Calif. (PRWEB) , ... December 05, 2019 , ... Abide, ... asleep over 25 million times this year using Bible-based bedtime stories. Listeners have recovered ... minds. , According to the Center for Disease Control, one third of Americans suffer ...
(Date:12/4/2019)... ... December 04, 2019 , ... A November 12 article ... offer them as public transit options. The article highlighted the life-changing or life-ending consequences ... to a bed to a rider fatality after an incident with a vehicle. Los ...
Breaking Medicine News(10 mins):